Drug Trial Radar · NCT05848011
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Sep 28, 2023
Primary completion
Feb 19, 2026
Study completion Mar 16, 2026
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- First posted
- May 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to the standard of care (SOC) of docetaxel and prednisone. About 150 participants with mCRPC will be enrolled. Participants will be randomized in a 2:1 ratio to receive lorigerlimab with docetaxel and prednisone (experimental arm) or docetaxel and prednisone alone (standard-of-care arm). Lorigerlimab+docetaxel or docetaxel will be administered intravenously (IV) in clinic on Day 1 of each 3-week cycle. Prednisone will be administered orally twice daily. Lorigerlimab will be administered for up to 35 cycles. Docetaxel and prednisone will be administered up to 10 cycles until treatment discontinuation criteria are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI) and prostate-specific antigen (PSA) blood tests. Participants will be asked to complete questionnaires about their health and well-being. Routine examinations and blood tests will be performed and evaluated by the study doctor. Participants who have disease progression standard-of-care arm have the option of continuing on the study to receive lorigerlimab monotherapy.
Conditions
- Androgen-Independent Prostatic Cancer
- Androgen-Independent Prostatic Neoplasms
- Prostate Cancer Recurrent
- Androgen-Insensitive Prostatic Cance
- Androgen-Resistant Prostatic Cancer
- Hormone Refractory Prostatic Cancer
- Immunotherapy
- Immune Checkpoint Inhibitor
- Inhibitory Checkpoint Molecule
Interventions
lorigerlimabBiological
Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4
docetaxelDrug
Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
PrednisoneDrug
A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median radiographic progression free survival (rPFS) determined by investigator review.Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years
Locations
61 sites in 10 countries. Site status is shown where the registry gives one.
United Medical Group
Miami, Florida
Orlando Health Cancer Institute
Orlando, Florida
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Nebraska Cancer Specialists
Grand Island, Nebraska
Icahn School of Medicine at Mount Sinai
New York, New York
SUNY Upstate Medical University
Syracuse, New York
MD Anderson Cancer Center
Houston, Texas
START Mountain Region
West Valley City, Utah
University of Virginia Health System Cancer Center
Charlottesville, Virginia
Concord Repatriation General Hospital
Concord, Australia
Peter MacCallum Cancer Centre
North Melbourne, Australia
North Shore Private Hospital
St Leonards, Australia
Westmead Hospital
Westmead, Australia
Cliniques universitaires Saint-Luc (CUSL), Brussels
Brussels, Belgium
UZ GENT
Ghent, Belgium
Centre Hospital de l'Ardenne
Libramont, Belgium
CHU de Liège
Liège, Belgium
MHAT Dr. Tota Venkova
Gabrovo, Bulgaria
Comprehensive Cancer Center
Plovdiv, Bulgaria
UMHAT Sv. Ivan Rilski
Sofia, Bulgaria
Institut Bergonie
Bordeaux, France
Clinique Victor Hugo
Le Mans, France
Centre Léon Bérard
Lyon, France
Centre Antoine Lacassagne
Nice, France
Institut Mutualiste Montsouris
Paris, France
Centre Hospitalier Quimper
Quimper, France
CHP Saint Grégoire
Saint-Grégoire, France
Hia Begin
Saint-Mandé, France
Hopital Foch
Suresnes, France
Institut Gustave Roussy
Villejuif, France
LTD High Tech Hosp Medcenter
Batumi, Georgia
First University Clinic TSMU
Tbilisi, Georgia
LTD Consilium Medulla
Tbilisi, Georgia
Ltd Gidmedi
Tbilisi, Georgia
LtD L.M.National Urology Center
Tbilisi, Georgia
LTD MMT Hospital
Tbilisi, Georgia
LTD Todua Clinic
Tbilisi, Georgia
Onc. Scient. Research Center
Tbilisi, Georgia
Przychodnia Lekarska KOMED
Konin, Poland
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.